Abstract

Recently, extracorporeal shock wave therapy (ESWT) has been shown to be a novel therapy for carpal tunnel syndrome (CTS). However, previous studies did not examine the diverse effects of different-session ESWT for different-grades CTS. Thus, we conducted a randomized, single-blind, placebo-controlled study. Sixty-nine patients (90 wrists) with mild to moderate CTS were randomized into 3 groups. Group A and C patients received one session of radial ESWT (rESWT) and sham eESWT per week for 3 consecutive weeks, respectively; Group B patients received a single session of rESWT. The night splint was also used in all patients. The primary outcome was Boston Carpal Tunnel Syndrome Questionnaire (BCTQ) points, whereas secondary outcomes included the sensory nerve conduction velocity and cross-sectional area of the median nerve. Evaluations were performed at 4, 10, and 14 weeks after the first session of rESWT. Compared to the control group, the three-session rESWT group demonstrated significant BCTQ point reductions at least 14 weeks, and the effect was much longer lasting in patients with moderate CTS than mild CTS. In contrast, the effect of single-session rESWT showed insignificant comparison. rESWT is a valuable strategy for treating CTS and multiple-session rESWT has a clinically cumulative effect.

Highlights

  • Gelberman et al found a significantly higher pressure in the intra-carpal canal in patients with Carpal tunnel syndrome (CTS) compared with patients without CTS (32 mmHg vs. 2.5 mmHg)[4]

  • To the best of our knowledge, the present study is the first prospective, randomized, single-blind, placebo-controlled study to investigate the dose-dependent efficiency of rESWT for treating patients with mild to moderate CTS

  • The effect of single-session rESWT is insignificant for both mild and moderate CTS compared with the control group

Read more

Summary

Introduction

Gelberman et al found a significantly higher pressure in the intra-carpal canal in patients with CTS compared with patients without CTS (32 mmHg vs. 2.5 mmHg)[4]. ESWT has been extensively clinically applied in treating miscellaneous musculoskeletal disorders like plantar fasciitis, chronic calcifying tendonitis, and lateral epicondylitis[10,12]. Both fESWT and rESWT have received increased attention as being a safe and novel therapy for CTS11,13–15. In 2015, we reported the first prospective, randomized, double-blind, placebo-controlled study, and revealed the effective benefit of rESWT for treating CTS after 3 months follow-up[11]. We performed a larger, prospective, randomized, single-blind, placebo-controlled study to investigate the dose-dependent effect of rESWT in patients with mild to moderate CTS

Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call